高血压增殖性胆视网膜病变 (choriorretinopathy) 是一种高血压增殖性胆视网膜病变
Guilherme Portas-Almeida1, Catarina Oliveira Rodrigues, Rita Guerra Pinto
1Ophthalmology Department, São José Local Health Unit, Lisbon, Portugal.
Retinal cases & brief reports
|September 29, 2025
概括
严重的高血压可以导致通过高血压胆红蛋白病变和新血管化导致视力丧失. 泛视网膜光凝 (PRP) 无效,突显了严格控制血压的必要性.
科学领域:
- 眼科医生 眼科 眼科
- 血管医学 血管医学
背景情况:
- 高血压胆色素变异症是不受控制的高血压的严重并发症.
- 前段新血管化可能是视网膜缺血的次要原因.
研究的目的:
- 为了呈现一个高血压胆色素变异病例与前段新血管化.
- 评估治疗反应,特别是对泛视网膜光凝 (PRP) 的反应.
主要方法:
- 病例报告详细介绍了一名患有严重,不受控制的高血压的患者.
- 诊断成像包括后视镜,光素血管学和氨酸绿色血管学.
- 治疗包括内抗VEGF注射和PRP.
主要成果:
- 患者呈现出渐进的视力丧失和前段新血管化.
- 血管造影证实了严重的视网膜缺血症和延迟的胆道 perfusion.
- 起初,PRP和抗VEGF可以控制新血管化,但它会复发,需要进一步的抗VEGF治疗.
结论:
- 在高血压胆红素病的胆红素缺血可能是PRP的耐火性.
- 有效的管理需要严格的全身高血压控制.
- 定期监测对于预防危及视力的并发症至关重要.
关键词:
前段新血管化 前段新血管化抗VEGF治疗疗法是一种治疗方法.冠状腺缺血症 冠状腺缺血症在高血压的高血压.高血压胆固醇病变是一种高血压胆固醇病变.高血压视网膜病变是一种高血压视网膜病变.印度氨酸绿色血管学泛视网膜光凝聚 泛视网膜光凝聚更多相关视频
12:28Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies
Published on: March 12, 2022
4.2K
08:10An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
Published on: January 25, 2019
8.2K
相关概念视频
Glaucoma: Overview
1.2K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.2K
Open Angle Glaucoma: Treatment
963
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
963
